Anbio Biotechnology

NNNNNasdaq Germany Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$817.302 M

$5.68 +8.19%

Close of 21 Sept 2026

Revenue

$8.65M

#3187 by revenue

Earnings

$6.40M

#2134 by earnings

Shares outstanding

—

Latest filing cover page

P/E ratio

127.6

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#6Intellia TherapeuticsNTLA$1.71B
#7Achieve Life SciencesACHV$828.4M
#8Anbio BiotechnologyNNNN$817.3M
#9QuidelOrthoQDEL$744.7M
#10Alpha TeknovaTKNO$447.8M

What if Anbio Biotechnology were worth as much as…

Open the what-if tool →

Gold $30.3T

$210,395.45

Per share 37,041× higher

Bitcoin $1.72T

$11,952.11

Per share 2,104× higher

Nvidia $5.48T

$38,083.34

Per share 6,705× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Anbio Biotechnology are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.